logo
Bread Sold in 6 States Recalled Due to Glass Contamination

Bread Sold in 6 States Recalled Due to Glass Contamination

Epoch Times02-05-2025

A Glenn Dale, Maryland-based company has voluntarily recalled three types of its frozen bread products that had been distributed across six states.
The loaves were recalled due to glass contamination.
Upper Crust Crest Hill Bakery, also known as Upper Crust Bakery LP, announced on April 12 that it was recalling 89 cases of its 4-ounce Ancient Grains Hoagie Roll (Lot No. 90), 699 cases of its 18-ounce Multigrain Sourdough (Lot no. 90), and 30 cases of its 20-ounce Whole Grain Multigrain product (Lot no. 92), according to an FDA
The enforcement report shows that the products were distributed to retailers or wholesalers in Pennsylvania, California, Connecticut, Maryland, Delaware, and Ohio.
'Glass contamination can happen at several stages of food production due to equipment breakage, packaging accidents, and inadequate cleanup,' Darin Detwiler, a Northeastern University professor, food safety expert, and Alliance for Recall Ready Communities adviser, said in an email to NTD, a sister media outlet of The Epoch Times. 'This risk is why food facilities have strict policies called Glass and Brittle Plastic Control Programs—but lapses can still happen.'
Specifically, glass fragments were found on top of the three bread products. Neither the FDA nor the Upper Crust Crest Hill Bakery responded to requests for comment by press time.
Related Story
5/1/2025
The company says on its website that it partially bakes, then freezes, bread and pizza dough made with non-genetically modified ingredients. The products are then sold to wholesalers and food retailers.
The recall was initiated on April 12 and classified as a Class II recall by the FDA on April 25. The weekly enforcement report was published on April 30.
'The gap reflects the time needed for the FDA to review company data, assess risk, and assign a classification,' Detwiler said. 'The recall was not enforced late—it was logged into the weekly reporting system after classification.'
The recall was classified as a Class 2 event, which the FDA
Class 2 indicates a moderate risk to consumers, Detwiler said, while Class 1 indicates a higher risk level.
'What stands out here is the specific location of the hazard, which was on top of the bread,' he said.
'If this contamination was external and visible, it changes how the risk is perceived. It may also explain the Class II designation rather than a Class I, which is more typical for glass recalls.
'Identifying which lots went to which stores takes time and coordination, and more retail partners means more consumer alerts and more room for error,' Detwiler said. 'When recalled products appear under multiple store names, public confusion and brand damage can multiply.'
From NTD News

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

GSK (GSK) Gains FDA Approval for Benlysta Autoinjector for Lupus Treatment
GSK (GSK) Gains FDA Approval for Benlysta Autoinjector for Lupus Treatment

Yahoo

time2 hours ago

  • Yahoo

GSK (GSK) Gains FDA Approval for Benlysta Autoinjector for Lupus Treatment

GSK plc (NYSE:GSK) is one of the 11 best European stocks to invest in. On June 24, the company announced receipt of FDA approval for a 200 mg/mL autoinjector of Benlysta (belimumab) for the treatment of active lupus nephritis (LN). The approval applies to children aged five years and above. A pharmacist looking at a prescription bottle of gastrointestinal drugs. Benlysta autoinjector is the first-of-its-kind treatment option for at-home administration. The drug is a B-lymphocyte stimulator (BLyS)-specific inhibiting monoclonal antibody. It works by binding to soluble BLyS, which inhibits the survival of B cells, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells. It does not bind B cells directly. The 200 mg/mL autoinjector was previously approved for pediatric patients with active systemic lupus erythematosus (SLE) in 2024. Benlysta was the first and only approved biologic for both SLE and lupus nephritis in over 50 years, including for the pediatric population. The autoinjector will be available for patients and their caregivers immediately. GSK plc (NYSE:GSK) is a UK-based global biopharmaceutical company. It researches, develops, and sells medicines and vaccines for infectious diseases, HIV, respiratory conditions, cancer, and immune-related disorders. Its key products include Shingrix (shingles vaccine), Nucala (asthma), and HIV treatments through its ViiV Healthcare joint venture. While we acknowledge the potential of GSK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

This common kitchen herb ingredient could help target or slow Alzheimer's
This common kitchen herb ingredient could help target or slow Alzheimer's

New York Post

time2 hours ago

  • New York Post

This common kitchen herb ingredient could help target or slow Alzheimer's

Experts believe they've identified a chemical compound in certain herbs that could help mitigate or prevent Alzheimer's disease — but before anyone makes a run for the spice rack, there are a few catches. In a study published in the journal Antioxidants earlier this year, researchers from the Scripps Research Institute identified a compound called carnosic acid, which is prevalent in rosemary and sage. Advertisement The compound could prove therapeutic for neurodegenerative disorders, including Alzheimer's disease, the experts concluded. Carnosic acid contains 'striking antioxidant [and] anti-inflammatory properties,' the researchers wrote in the findings. Scripps Research postdoctoral associate Piu Banerjee and board-certified neurologist Dr. Stuart Lipton, based in California, spoke with Fox News Digital about the results. 'In this study, we observed that administering this drug to mice that had advanced Alzheimer's-like disease significantly improved the number of neurons, as well as the number of synapses or connections between the brain cells,' the team said. Advertisement 4 Experts believe they've identified a chemical compound, carnosic acid, in certain herbs like rosemary and sage that could help mitigate or prevent Alzheimer's disease. Brent Hofacker – The experts added, 'It also reduced inflammation that is caused by the current anti-amyloid antibody therapies. We also observed an improvement in the learning and memory behavior of the mice that received the drug.' Banerjee and Lipton also noted that carnosic acid is a 'prodrug,' meaning it's inactive at first — but once it enters the body, it's activated by oxidative and inflammatory stress. 'It specifically targets cells undergoing oxidative and inflammatory stress, without affecting the healthy, normal brain cells,' Banerjee said. Advertisement 'This further makes it a safe option for therapeutics.' The experts agreed that carnosic acid could potentially improve the inflammation that generally occurs in most aging brains. There are cautions, however. Advertisement Courtney Kloske, director of scientific engagement for the Chicago-based Alzheimer's Association, told Fox News Digital that studies based on a mouse model of Alzheimer's can be helpful but are not conclusive. 4 Experts say carnosic acid could improve inflammation occurring in most aging brains. LIGHTFIELD STUDIOS – 'Models are important in helping us understand the basic biology of the disease, but we need human studies in representative populations for ideas to be fully validated,' Kloske said. 'Therefore, while these are intriguing findings, more research is needed to understand the impacts and outcomes of these compounds on people living with, or at risk for, Alzheimer's.' Cooking sage and rosemary won't provide the full anti-inflammatory effects, Banerjee and Lipton stressed. 4 'We need human studies in representative populations for ideas to be fully validated,' Courtney Kloske, director of scientific engagement for the Chicago-based Alzheimer's Association, says about the limitations of the information. – 'Critically, one cannot take sufficient herbs safely to produce the same effect as our new drug,' Banerjee said. The study, funded in part by the National Institutes of Health, did have some limitations, the researchers acknowledged. Advertisement Kloske advised that, at this point, 'no one should consume these herbs (or carnosic acid) to prevent or treat Alzheimer's or other cognitive impairment.' 4 According to Scripps Research postdoctoral associate Piu Banerjee and board-certified neurologist Dr. Stuart Lipton, cooking sage and rosemary won't provide the full anti-inflammatory effects. Ganna – Dr. Lee Murray, a neurologist in Jackson, Tennessee, echoed Kloske's concerns. 'Before patients start incorporating rosemary and sage in every dish they eat, we need to remember these studies are pre-clinical,' Murray told Fox News Digital. Advertisement 'Currently, there is insufficient clinical evidence to recommend rosemary and sage as a standard therapy for Alzheimer's dementia.' Murray, however, said the data 'is encouraging' and opens the door to additional pathways for potential therapeutics. Banerjee said she hopes that 'our drug will start human clinical trials soon.' She added, 'If it proves to be effective, it will be a great new drug for those suffering from Alzheimer's … From the results of our animal studies, we are cautiously optimistic for its success in human clinical trials.'

Zeke Cohen calls for Baltimore City Council hearing on behavioral crisis response
Zeke Cohen calls for Baltimore City Council hearing on behavioral crisis response

Yahoo

time2 hours ago

  • Yahoo

Zeke Cohen calls for Baltimore City Council hearing on behavioral crisis response

Baltimore City Council President Zeke Cohen wants the city to take a closer look at behavioral health crisis response issues by adding another hearing to the council's busy oversight schedule this summer. Cohen's request comes after three people experiencing behavioral health crises died in an eight-day period this month. June 17: Bilal Yusuf-Muhammad 'B.J.' Abdullah Jr, 36, was shot and killed after exchanging gunfire with Baltimore Police Department officers near the Upton subway station. June 24: An unidentified man approached a police cruiser stopped at West Franklin Street and North Franklintown Road and walked repeatedly into the middle of the road. An officer tried to restrain the man and called for EMS, but the man became unresponsive before they arrived and died at a hospital hours later, according to the Maryland Office of the Attorney General. June 25: Police shot and killed Pytorcarcha Brooks, 70, on Mosher Street. Police said Brooks brandished a knife and lunged at one officer before another officer at the scene fired his weapon. 'These tragedies are a heartbreaking reminder that far too many Baltimoreans suffer in silence,' Cohen said in a statement Friday.'Today I am calling for a hearing in the City Council's Public Safety Committee to examine our behavioral health crisis response systems.' Councilman Mark Conway, who chairs the Public Safety Committee, has sought to hold council hearings on the city's opioid crisis — an epidemic with clear ties to the behavioral health challenges facing Baltimore. The council's upcoming schedule includes hearings related to the opioid crisis on July 9 and July 16, but they will be taken up by the Public Health & Environment Committee. Conway's advocacy on the opioid crisis put him at odds with Mayor Brandon Scott, who argued earlier this year that holding public hearings would jeopardize Baltimore's ongoing legal efforts to hold pharmaceutical companies responsible for distributing drugs in the city. The city has already secured more than $400 million in settlements, though a judge ruled that jurors last November awarded Baltimore 'grossly excessive' compensation from pharmaceutical titans McKesson and AmerisourceBergen. This case remains ongoing and could be headed for a retrial if the city does not accept the decision that reduced jurors' original verdict by more than $200 million. Other notable oversight hearings on the council's upcoming schedule include transportation (July 10), crime reduction/violence prevention (July 15), psychiatric rehabilitation programs (July 23), and recovery homes/substance abuse clinics (July 30). Have a news tip? Contact Carson Swick at cswick@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store